Copyright © 2004 by the European Society of Cardiology.
Clinical research
The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies
a TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
b New England Research Institutes, Watertown, MA, USA
c Department of Medicine, University of California San Francisco and Department of Medical Affairs, Genentech, Inc, San Francisco, CA, USA
d Department of Cardiology, UH Gasthuisberg, Leuven, Belgium
Received December 21, 2003;
revised April 8, 2004;
accepted April 29, 2004
* Corresponding author. Tel.: +1-617-278-0145; fax: +1-617-734-7329
E-mail address: dmorrow{at}partners.org
This paper was guest edited by C. Granger, Duke University Medical Center, Durham, USA
Aims Interpreting the results and practice implications of clinical studies requires accurate characterisation of the baseline risk of the population. We evaluated the Thrombolysis in Myocardial Infarction (TIMI) risk score for STEMI as a tool to describe and compare the risk profile of populations enrolled in three clinical trials (InTIME-II, ASSENT-2 and MAGIC) and the National Registry of Myocardial Infarction.
Methods and Results The risk score was calculated for each patient 
and the frequency distribution plotted for each population. The Risk Score Profiles were compared using the Kolmogorov–Smirnov test. The Risk Score Profile demonstrated a striking concordance between the baseline risk of patients in InTIME-II and ASSENT-2 (median scores in each=
, 
. In contrast, the distributions in MAGIC (designed to enroll high risk) and NRMI (registry) were shifted significantly toward higher risk (median scores=
for MAGIC and 
in NRMI, 
for each vs. InTIME-II). A graded relationship between the risk score and mortality was evident in each study 
.
Conclusions The frequency distribution of the TIMI Risk Score, or similar tools for risk assessment, may be used to quantify and readily compare the risk profile of populations enrolled in clinical studies.
Key Words: Clinical trials • Prognosis • Myocardial infarction • Mortality • Risk factors
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. S. Alpert A Plethora of Prognostic Pearls Circulation, September 23, 2008; 118(13): 1312 - 1313. [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Wiviott, D. A. Morrow, P. D. Frederick, E. M. Antman, and E. Braunwald Application of the Thrombolysis In Myocardial Infarction Risk Index in Non-ST-Segment Elevation Myocardial Infarction: Evaluation of Patients in the National Registry of Myocardial Infarction J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1553 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald The Year in Non--ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., September 6, 2005; 46(5): 906 - 919. [Full Text] [PDF]
|
|